While the nocodazole treatment led to a robust phosphorylation of FOXO1 by PLK1, the co-treatment caused significant reduction of FOXO1 phosphorylation as well as a strong induction in the expression of Bim, a downstream target of FOXO1, which further substantiates our working hypothesis and validates the mechanism of action of this novel combination therapy for advanced PCa (Figure S4). Here, BCL2L11 is linked to posterior cortical atrophy.